Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent
clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …

Diabetic cardiomyopathy (DCM) is one of the leading causes of heart failure in patients with
diabetes mellitus, with limited effective treatments. The cardioprotective effects of sodium …

Background Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and
renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated …

Abstract Background Type 2 diabetes (T2D) is associated with generalized vascular
dysfunction characterized by increases in large artery stiffness, endothelial dysfunction, and …

Recent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2)
inhibitors, which inhibit renal glucose reabsorption, have reported beneficial cardiovascular …

Diabetes mellitus currently affects over 350 million patients worldwide and is associated with
many deaths from cardiovascular complications. Sodium–glucose co-transporter 2 (SGLT-2) …

Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …

Background Sodium‐glucose cotransporter‐2 inhibitors are cardioprotective independent of
glucose control, as demonstrated in animal models of acute myocardial ischemia and …

The endothelial cell response to glucose plays an important role in both health and disease.
Endothelial glucose-induced dysfunction was first studied in diabetic animal models and in …